Venaxis Inc  

(Public, NASDAQ:APPY)   Watch this stock  
Find more results for Donald Welch�
1.61
-0.05 (-3.01%)
Sep 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.61 - 1.69
52 week 1.55 - 3.88
Open 1.64
Vol / Avg. 44,117.00/137,621.00
Mkt cap 51.44M
P/E     -
Div/yield     -
EPS -0.51
Shares 30.99M
Beta 0.81
Inst. own 28%
Sep 18, 2014
Venaxis Inc at Craig-Hallum Alpha Select Conference
Sep 12, 2014
Venaxis Inc at Aegis Capital Corp Healthcare & Technology Conference
Sep 9, 2014
Venaxis Inc at Rodman & Renshaw Global Investment Conference
Aug 14, 2014
Venaxis Inc at Canaccord Genuity Growth Conference
Aug 11, 2014
Venaxis Inc Analyst Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -21666.95%
Operating margin - -21585.84%
EBITD margin - -20944.62%
Return on average assets -41.30% -68.92%
Return on average equity -51.65% -102.78%
Employees 20 -
CDP Score - -

Address

1585 South Perry Street
CASTLE ROCK, CO 80104
United States - Map
+1-303-7942000 (Phone)
+1-303-7988332 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Venaxis, Inc., formerly AspenBio Pharma, Inc., is focused on products that addresses unmet human diagnostic needs. The Company is developing a multi-marker blood test panel, APPY1, which is focused to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2-20) that present with abdominal pain. As on December 31, 2012, the Company�s research and development activities are focused primarily on a human acute appendicitis blood-based test. APPY1 is a multi-marker blood test panel of biomarkers consisting of the Company�s patented MRP 8/14 (also known as S100A8/A9 or calprotectin) and C-reactive protein (CRP), along with White Blood Cell count (WBC). These results are displayed on the display screen and are also included on a patient print-out from the APPY reader, which is a small bioanalyzer (instrument or reader)

Officers and directors

Stephen T. Lundy President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jeffrey G. McGonegal Chief Financial Officer, Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Donald R. Hurd Senior Vice President, Chief Commercial Officer
Age: 62
Bio & Compensation  - Reuters
Gail S. Schoettler Ph.D. Non-Executive Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Susan A. Evans Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Daryl Jay Faulkner Independent Director
Age: 65
Bio & Compensation  - Reuters
John H. Landon Independent Director
Age: 73
Bio & Compensation  - Reuters
David E. Welch Independent Director
Age: 67
Bio & Compensation  - Reuters